Apoptotic effect of tolfenamic acid on MDA-MB-231 breast cancer cells and xenograft tumors

Journal of Clinical Biochemistry and Nutrition

Volumn 53, Issue 1, 2013, Pages 21-26

  Kim, Hyeong Jin ^a   Cho, Sung Dae ^b   Kim, Jin ^a   Kim, So Jung ^a   Choi, Changsun ^c   Kim, Jong Suk ^b   Nam, Jeong Seok ^d   Kwon, Ki Han ^e   Kang, Kyung Sun ^f   Jung, Ji Youn ^a  

^a Kongju National University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Chung Ang University   (South Korea)

^d Gachon University   (South Korea)

^e Kwangju University   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Apoptosis; MDA MB 231; P21; P53; Tolfenamic acid

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TOLFENAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR VOLUME; XENOGRAFT;

EID: 84881295889     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.12-78     Document Type: Article

References (22)

1. 2), an antiinflammatory fenamate. Arch Pharm Res 1996;19:160-162.
2. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal antiinflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 2009;8:1207-1217.
3. Kim JH, Jung JY, Shim JH, et al. Apoptotic effect of tolfenamic acid in KB human oral cancer cells: possible involvement of the p38 MAPK pathway. J Clin Biochem Nutr 2010;47:74-80.
4. Lee SH, Bahn JH, Whitlock NC, Baek SJ. Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 2010;29:5182-5192.
5. Papineni S, Chintharlapalli S, Abdelrahim M, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009;30:1193-1201.
6. Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Phamacol 2004;68:1345-1352.
7. Sun SY, Haij N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96:662-672.
8. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009;30:1127-1130.
9. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2009;9:402-412.
10. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99-163.
11. Moll UM, Marchenko N, Zhang XK. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 2006;25:4725-4743.
12. Nigam M, Ranjan V, Srivastava S, Sharma R, Balapure AK. Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA-MB-231 human breast cancer cells. Life Sci 2008;82:577-590.
13. Eslin D, Sankpal UT, Lee C, et al. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog 2011;28:215-228.
14. Basha R, Ingersoll SB, Sankpal UT, et al. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011;122:163-170.
15. Choi KH, Shim JH, Huong LD, Cho NP, Cho SD. Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma. Oral Dis 2011;17:469-475.
16. Lee SH, Bahn JH, Choi CK, et al. ESE-l/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008;7:3739-3750.
17. Allen RT, Hunter WJ 3rd, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods 1997;37:215-228.
18. Benson RS, Heer S, Dive C, Watson AJ. Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol 1996;270:C1190-C1203.
19. Oda K, Arakawa H, Tanaka T, et al. p53AIPl, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-862.
20. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIPl regulates the mitochondrial apoptotic pathway. Cancer Res 2002;62:2883-2889.
21. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-126.
22. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-9040.